FLT3 and acute myeloid leukemia: Based on these preclinical findings, a phase 2 trial was designed to study the efficacy and safety of the combination DDecitabine, Venetoclax, and FLT3 TKI in front-line treatment with FLT3- mutated AML >60 years and R/R patients >18 years [56].